Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Minimum effective dose of inhaled azacitidine, defined as the dose required to induce the re-expression of any of the relevant 5 candidate tumor suppressor genes by two fold between pre and post treatment bronchial biopsies in 50% of evaluable patients
研究概览
简要总结
This pilot phase I trial studies the side effects and best dose of azacitidine in treating patients with lung cancer that is stage IV or has returned after previous treatments (recurrent). Azacitidine is a drug used in chemotherapy that may stop tumor cells from growing or spreading by activating genes that help prevent cancer growth, called tumor suppressor genes. As people age, these genes are silenced by a chemical reaction that occurs naturally in the body, or by exposure to environmental factors such as smoking. Azacitidine may help reverse this process and restore the function of the tumor suppressor genes. Delivering azacitidine directly into the lungs by inhalation may work better in treating lung cancer.
详细描述
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) and toxicity of inhaled Vidaza® (azacitidine) with special emphasis on pulmonary toxicity.
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetics of inhaled Vidaza®. II. To determine the changes in global methylation patterns in the bronchial epithelium (bronchial tissue samples) pre and post treatment.
III. To determine the changes in methylation patterns in the exhaled breath. IV. To evaluate the efficacy of inhaled Vidaza® on intra-thoracic tumors (response rate by Response Evaluation Criteria in Solid Tumors [RECIST] criteria for intrapulmonary lesions).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically proven (either histologic or cytologic) diagnosis of stage IV or recurrent non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
- •Patient has received at least one prior standard chemotherapy or targeted therapy for treatment of lung cancer
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Absolute neutrophil count (ANC) >= 1,500 cells/ul
- •Platelets >= 100,000 cells/ul
- •Hemoglobin >= 9.0 g/dl (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= g/dl is acceptable)
- •Serum creatinine =< 1.5 x upper limit of normal (ULN)
- •Total bilirubin < 2.0 times the institutional upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULN
- •Adequate pulmonary reserve defined as adequate airflow defined by a measured forced expiratory volume (FEV1) not less than 50% of the predicted value and adequate pulmonary reserve as evidenced by a FEV1/forced vital capacity (FVC) ratio of 65% or greater
- •Patient must sign study specific informed consent prior to study entry
- •Women of childbearing potential must have:
- •A negative serum or urine pregnancy test (sensitivity =< 25 IU human chorionic gonadotropin [HCG]/L) within 72 hours prior to the start of study drug administration
- •Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy
排除标准
- •Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study
- •Contraindication to or unwillingness to undergo study related procedures including a repeat bronchoscopy
- •Participation in an investigational drug or device study or treatment with any antineoplastic agent within 14 days of the first day of dosing on this study
- •History of significant bleeding disorder unrelated to cancer, including:
- •Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
- •Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
- •History of hypersensitivity to mannitol
- •Unwillingness or inability to comply with the study protocol for any other reason
- •Women who:
- •Are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or
- •Have a positive pregnancy test at baseline, or
- •Are pregnant or breastfeeding
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness
研究组 & 干预措施
Treatment (azacitidine)
Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
干预措施: Azacitidine (Drug)
Treatment (azacitidine)
Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (azacitidine)
Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
干预措施: Pharmacological Study (Other)
结局指标
主要结局
Minimum effective dose of inhaled azacitidine, defined as the dose required to induce the re-expression of any of the relevant 5 candidate tumor suppressor genes by two fold between pre and post treatment bronchial biopsies in 50% of evaluable patients
时间窗: Up to day 28 after the first course of treatment
The data will be analyzed and presented in descriptive fashion.
次要结局
未报告次要终点